Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.
Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.
复制标题
DOI:
10.1007/s11883-011-0219-7
复制
发表时间:
2012-02
影响因子:
5.8
通讯作者:
Linton, MacRae F.
中科院分区:
文献类型:
--
作者:
Sampson, Uchechukwu K.;Fazio, Sergio;Linton, MacRae F.
This review captures the existence, cause, and treatment challenges of residual cardiovascular risk (CVR) after aggressive low-density lipoprotein cholesterol (LDL-C) reduction. Scientific evidence implicates low high-density lipoproteins cholesterol (HDL-C) and high triglycerides (TG) in the CVR observed after LDL-C lowering. However, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial with fenofibrate, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) study with torcetrapib, and the recently terminated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) study with niacin, do not clearly attribute risk reduction value to HDL-C/TG modulation. The optimum approach to long-term lipid-modifying therapies for CVR reduction remains uncertain. Consequently, absolute risk modulation via lifestyle changes remains the centerpiece of a strategy addressing the physiological drivers of CVR associated with HDL-C/TG, especially in the context of diabetes/metabolic syndrome.
登录
查看更多内容
影响因子:
5.3
作者:
Assmann, G;Schulte, H;Huang, YD
通讯作者:
Huang, YD
影响因子:
158.5
作者:
Barter, Philip;Gotto, Antonio M.;Fruchart, Jean-Charles
通讯作者:
Fruchart, Jean-Charles
DOI:
10.1161/atvbaha.107.148817
发表时间:
2008-01-01
影响因子:
8.7
作者:
Barter, Philip J.;Rye, Kerry-Anne
通讯作者:
Rye, Kerry-Anne
影响因子:
120.7
作者:
de Lemos, JA;Blazing, MA;Braunwald, E
通讯作者:
Braunwald, E
影响因子:
--
作者:
Cui, YD;Blumenthal, RS;Bush, TL
通讯作者:
Bush, TL